E-Mail
IMAGE: Fusions detection in GEM ExTra. (A) Fusions detected by tumor type. (B) Fusion s detected in tumors types with RNA only findings. For those main fusion genes (e.g., BRAF) that were. view more
Credit: Correspondence to - Thomas Royce - TRoyce@ashion.com
Oncotarget published Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra® which reported that the authors developed and analytically validated a comprehensive genomic profiling assay, GEM ExTra, for patients with advanced solid tumors that uses Next Generation Sequencing to characterize whole exomes employing a paired tumor-normal subtraction methodology.
The assay detects single nucleotide variants, indels, focal copy number alterations, TERT promoter region, as well as tumor mutation burden and microsatellite instability status.
Ashion Analytics to Present Data on the Value of Comprehensive Genomic Profiling of Gastrointestinal Cancers by Utilizing the GEM ExTra® Test
News provided by
Share this article
Share this article
PHOENIX, Jan. 15, 2021 /PRNewswire/ Ashion Analytics LLC, a CLIA-certified and CAP-accredited clinical laboratory announced today that they will present data at the 2021 American Society for Clinical Oncology Gastrointestinal (ASCO GI) virtual meeting.
Abstract #109
Title:
Genomic profiling of gastrointestinal cancers by comprehensive tumor-normal sequencing
Authors: Fadel S. Alyaqoub, Pawan Noel, Szabolcs Szelinger, Thanemozhi G. Natarajan, Susan M. Dombrowski, Audrey A. Ozols, Laurie J. Goodman, Janine LoBello, Thomas Royce, Gargi D. Basu